The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
Clinical trial NCT04206787 · COMPLETED
Trial details
- NCT number
- NCT04206787
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2020-05-20
- Primary completion
- 2023-12-18
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.